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Amyotrophic lateral sclerosis (ALS) is themost common adult-onset motor neuron disease.
More than 90% of ALS cases are sporadic, and the majority of sporadic ALS patients do
not carry mutations in genes causative of familial ALS; therefore, investigation speciﬁcally
targeting sporadic ALS is needed to discover the pathogenesis.The motor neurons of spo-
radic ALS patients express unedited GluA2 mRNA at the Q/R site in a disease-speciﬁc and
motor neuron-selective manner. GluA2 is a subunit of the AMPA receptor, and it has a
regulatory role in the Ca2+-permeability of the AMPA receptor after the genomic Q codon
is replaced with the R codon in mRNA by adenosine–inosine conversion, which is medi-
ated by adenosine deaminase acting on RNA 2 (ADAR2). Therefore, ADAR2 activity may
not be sufﬁcient to edit all GluA2 mRNA expressed in the motor neurons of ALS patients.
To investigate whether deﬁcient ADAR2 activity plays pathogenic roles in sporadic ALS,
we generated genetically modiﬁed mice (AR2) in which the ADAR2 gene was condition-
ally knocked out in the motor neurons. AR2 mice showed an ALS-like phenotype with the
death of ADAR2-lacking motor neurons. Notably, the motor neurons deﬁcient in ADAR2
survivedwhen they expressed only edited GluA2 in AR2/GluR-BR/R (AR2res) mice, in which
the endogenous GluA2 alleles were replaced by the GluR-BR allele that encoded edited
GluA2. In heterozygous AR2 mice with only one ADAR2 allele, approximately 20% of the
spinal motor neurons expressed unedited GluA2 and underwent degeneration, indicating
that half-normal ADAR2 activity is not sufﬁcient to edit all GluA2 expressed in motor neu-
rons. It is likely therefore that the expression of unedited GluA2 causes the death of motor
neurons in sporadic ALS. We hypothesize that a progressive downregulation of ADAR2
activity plays a critical role in the pathogenesis of sporadic ALS and that the pathological
process commences when motor neurons express unedited GluA2.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most common adult-
onset motor neuron disease. ALS is characterized by progressive
paralysis with muscle wasting due to a selective loss of upper
and lower motor neurons. More than 90% of ALS cases are spo-
radic, whereas the remaining ALS cases have more than one other
affected family member (familial ALS) (Table 1). The majority
of sporadic ALS cases do not carry mutations in the genes that
are known to cause familial ALS, including Cu/Zn superoxide dis-
mutase (SOD1; Rosen et al., 1993; Jackson et al., 1997) FUS/TLS
(Kwiatkowski et al., 2009; Vance et al., 2009) and TARDBP (TDP-
43; Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al.,
2008; Yokoseki et al., 2008). In contrast, TDP-43 pathology in the
spinal cord motor neurons is considered to be a neuropathological
hallmark of sporadic ALS and is observed in most sporadic ALS
cases (Arai et al., 2006;Neumann et al., 2006;Hasegawa et al., 2008)
but not in the majority of familial ALS cases (Mackenzie et al.,
2007; Tan et al., 2007; Kabashi et al., 2008; Sreedharan et al., 2008;
Van Deerlin et al., 2008; Yokoseki et al., 2008; Kwiatkowski et al.,
2009; Vance et al., 2009; Deng et al., 2010). These lines of evidence
suggest that there is a common pathogenic mechanism of sporadic
ALS, which is not among the mutations in the genes that cause
ALS phenotype in familial ALS that have been identiﬁed to date.
Therefore, an investigation of the molecular abnormalities that
occur speciﬁcally in the pathological tissues of patients with spo-
radicALS is required to elucidate the disease pathogenesis. Because
molecular abnormalities found in the patients’ pathological tis-
sues include both the cause and the consequence of pathological
changes, it is necessary to demonstrate that the molecular changes
of interest induce the ALS phenotype in animals.
Wehavedemonstrated that theRNAeditingof GluA2,a subunit
of the l-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
(AMPA) receptor, at the glutamine/arginine (Q/R) site is inefﬁ-
cient in the motor neurons of sporadic ALS patients in a disease-
speciﬁc and motor neuron-selective manner (Takuma et al., 1999;
Kawahara et al., 2004). This is in marked contrast to the fact that
all GluA2 mRNA was edited in the motor neurons of control sub-
jects (Takuma et al., 1999; Kawahara et al., 2004), in patients with
motor neuron diseases other than sporadic ALS (Kawahara et al.,
2006), and in dying neurons in other neurodegenerative diseases,
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Table 1 | Uniform sporadic ALS and multiple different familial ALS.
Sporadic ALS Familial ALS
Incidence ∼90% ∼10%
ALS1 ALS6 ALS10 Other fALS
with known
gene mutations
Other fALS
with unknown
mutations
20–40% 4–5% 5–10% ∼10% 30∼60%
Age at
onset
64.6±11.5 Average; 43–46 y.o. Average; 44–45 y.o. Range 30–75 y.o.,
average 55 y.o.
Juvenile; ALS2, ALS4,
adult; ALS8, ALS9,
OPTN
Juvenile; ALS5,
adult; ALS3, 7
Causative
genes
Unknown Cu/Zn superoxide
dismutase (SOD1)
Fused in
sarcoma/translated in
liposarcoma(FUS/TLS)
TAR DNA-binding
protein (TDP)-43
(TARDBP )
ALS2; alsin, ALS4;
senataxin, ALS8; VAPB,
ALS9; ANG
ALS3; 18q21, ALS5;
15q15.1-q21.1,
ALS7; 20ptel
Inheritance Sporadic* AD AD/AR AD ALS2; AR, ALS4; AD,
ALS8; AD, dynactin;
PGRN; ANG; AD,
OPTN; AD/AR
Variable
Clinical
feature
Classic,
PBP>dementia
Multisystem
degeneration LMN
dominant
Classic, LMN dominant Classic,
PBP>dementia
Variable Variable
LMN>UMN, PBP,
dementia
LMN>UMN>
PBP>dementia
OPTN: Classic
Pathology UMN+LMN
degeneration
Degeneration of
Clarke’s neurons,
posterior horn, and
spinocerebellar tract
LMN and spinal cord
dominant degeneration
UMN+LMN
degeneration
Variable Variable
Bunina
body
+ − − + Unknown, OPTN(−) Unknown
TDP-43
pathology
+ − − + Unknown, OPTN(+) Unknown
Basophilic
inclusion
− − + − Unknown, OPTN(−) Unknown
RNA editing Under-edited Normal Unknown Unknown Unknown Unknown
Model
animal
AR2 mouse SOD1 transgenic
animal
FUS/TLS
knockout/transgenic
animal
TDP-43 knock-
out/transgenic
animal
ALS2 deﬁcient mouse Unknown
*A few% known gene mutations of FALS.
FALS, familial ALS; AD, autosomal dominant; AR, autosomal recessive; UMN, upper motor neuron; LMN, lower motor neuron; VAPB, vesicle-associated membrane
protein-associated protein B; OPTN, optineurin; classic, limb-onset classical ALS; PBP, progressive bulbar palsy; dementia, ALS with dementia; y.o., years old.
including the Purkinje cells of patientswith spinocerebellar degen-
eration (Paschen et al., 1994; Akbarian et al., 1995; Suzuki et al.,
2003; Kawahara et al., 2004). The high disease speciﬁcity warrants
an investigation of how inefﬁcient GluA2 RNA editing leads to
neuronal death.
Functional AMPA receptors are tetramers with various com-
binations of GluA1, GluA2, GluA3, and GluA4 that are produced
in a non-stochastic fashion. All the GluA subunits are expressed
in the human and rat spinal motor neurons (Tölle et al., 1993;
Kawahara et al., 2003; Sun et al., 2005). In mammalian neurons,
adenosine in the Q codon (CAG) is converted to inosine (A-
to-I conversion) in the Q/R site of virtually all GluA2 mRNA
(Figure 1A). This conversion results in the expression of the
GluA2 protein with R in the Q/R site because the CIG codon
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FIGURE 1 |The AMPA receptor and Ca2+-permeability.The GluA2 subunit
has four membrane domains (M1–M4). The glutamine/arginine (Q/R) site is
located in the M2 domain, and this editing site is the major determinant of the
Ca2+-permeability of the AMPA receptor. (A) An AMPA receptor with the
GluA2 subunit edited at the Q/R site (orange) in M2 (curved line in red). An
arginine (R) residue at the Q/R site prevents Ca2+ (yellow circle) from passing
through the channel pore. The AMPA receptors expressed on neurons contain
Q/R site-edited GluA2 in their assembly. (B) Ca2+-permeable AMPA receptors
do not contain the Q/R site-edited GluA2 subunit. Naturally occurring
Ca2+-permeable AMPA receptors consist of GluA1, GluA3, and GluA4
(yellow). In sporadic ALS, Ca2+-permeable AMPA receptors containing
unedited GluA2 (gray) are expressed in motor neurons.
is read as the CGG codon (R) during translation. Because the
A-to-I conversion at the Q/R site occurs only in the GluA2 sub-
unit, and because the AMPA receptor subunit with R at the Q/R
site critically regulates the Ca2+ permeability of AMPA recep-
tors, AMPA receptors can be impermeable to Ca2+ only when
they have Q/R site-edited GluA2 (Sommer et al., 1991; Nutt and
Kamboj, 1994; Geiger et al., 1995). This evidence indicates that
ALS motor neurons express abundant Ca2+-permeable AMPA
receptors with Q/R site-unedited GluA2 (Kwak and Kawahara,
2005) (Figure 1B). Because trafﬁcking of unedited GluA2 is more
efﬁcient (Greger et al., 2002), a considerably high proportion of
Ca2+-permeable functional AMPA receptors will be expressed in
the ALS motor neurons even with small amounts of unedited
GluA2 expression.
RNA editing at the GluA2 Q/R site is catalyzed by adenosine
deaminase acting on RNA 2 (ADAR2), a member of the ADAR
family (Figure 2; Higuchi et al., 2000). Therefore, investigating the
following questions would help to reveal a neuronal death-causing
mechanism in sporadic ALS: whether ADAR2-lacking motor neu-
rons die, whether deﬁcient ADAR2 is a direct cause of neuronal
death, and whether failure of the A-to-I conversion at the GluA2
Q/R site plays a critical role in the death of ADAR2-lacking motor
neurons. To address these aims, we developed mutant mice in
which the ADAR2 gene is targeted selectively to motor neurons
using the Cre-loxP system.
ADAR2 CONDITIONAL KNOCKOUT MICE (AR2)
It is not clear whether neuronal death occurs in neurons lack-
ing GluA2 Q/R site editing or in those lacking ADAR2 because
both systemic ADAR2-null mice (Higuchi et al., 2000) and genet-
ically engineered mice that cannot edit the GluA2 Q/R site
(Brusa et al., 1995) die young from status epilepticus. We crossed
ADAR2ﬂox/ﬂox mice with VAChT-Cre.Fast mice that displayed
restricted Cre expression under the control of the vesicular
acetylcholine transporter gene promoter in a subset of cholin-
ergic neurons, including the spinal motor neurons (Misawa
et al., 2003). By intercrossing the resulting ADAR2+/ﬂox/VAChT-
Cre.Fast mice, we obtained ADAR2ﬂox/ﬂox/VAChT-Cre.Fast (AR2)
mice (Figure 3A; Hideyama et al., 2010). The AR2 mice displayed
a slow, progressive motor dysfunction (Figures 3B,C) with a low
rotarod performance (Figure 4A) and grip strength (Figure 4B).
AR2 mice had slightly shorter life spans than the control mice
(Figure 4C). We investigated the AR2 mice for morphological
changes in the brain, spinal cord, motor nerves, and muscles,
as well as for functional changes of the neuromuscular units
at various postnatal periods. There were several degenerating
large neurons in the anterior horn (AHCs) with cytoplasmic vac-
uoles (Figure 5A). To evaluate the progression of motor neuron
death, we counted the number of motor neurons (SMI32-positive
AHCs) with and without ADAR2 immunoreactivity. The num-
ber of SMI32-positive AHCs in AR2 mice markedly decreased
between 1 and 2months of age and slowly decreased beyond 1 year
of age (Figure 5B). The motor neuron reduction is attributable
to the loss of ADAR2-lacking AHCs. The number of ADAR2-
positive AHCs remained unchanged after 2months of age. There
were darkly stained, degenerating axons with a decreased num-
ber of myelinated axons in the ventral roots (Figure 5C); these
were the consequence of AHC degeneration. Skeletal muscles
exhibited morphological characteristics of denervation, includ-
ing muscle ﬁber atrophy, centrally placed nuclei, and pyknotic
nuclear clumps. Electromyographic examination demonstrated
ﬁbrillation and fasciculation potentials, which are commonly
observed in the denervated and reinnervated muscle ﬁbers of
ALS patients (Hideyama et al., 2010). Some neuromuscular junc-
tions (NMJs) were abnormally innervated in AR2 mice; these
NMJs were either lacking innervation (denervated NMJs), or they
were innervated by ramiﬁed axons that innervated more than
one NMJ (reinnervated NMJs; Figure 5D). The proportion of
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FIGURE 2 | ADAR structure and RNA editing. (A)Three members of the
ADAR family. ADAR2 speciﬁcally catalyzes the A-to-I conversion at the GluA2
Q/R site, and two isoforms, ADAR2a and more abundantly ADAR2b, are
expressed in human brains and spinal cords (Aizawa et al., 2010). RBM, RNA
binding motif; NES, A nuclear export signal; NLS, A nuclear localization signal;
Alu, Alu sequences; (B). ADAR2 catalyzed adenosine to inosine conversion
(A-to-I RNA editing) in the double-stranded RNA structure in both coding and
non-coding regions of various transcripts expressed in mammalian brains.
When this type of editing occurs in the reading frame, the resulting changes
in the amino acid residues alter the biological function of the translated
molecules, including 5-HT2c receptors, GluAs, and GluKs. A-to-I RNA editing at
the GluA2 Q/R site is speciﬁcally catalyzed by ADAR2, a member of the
adenosine deaminase acting on RNA (ADAR) family. ADARs act on
double-stranded RNA, which is formed with the distal end of exon 11 that
includes the coding sequence for the Q/R site and the exon complementary
sequence in intron 11 of GluA2 pre-mRNA (Higuchi et al., 1993).
FIGURE 3 | Generation of conditional ADAR2 knockout mice (AR2). (A)
One loxP sequence (ﬁlled triangle) was inserted into intron 6 and another
into intron 9, which covers the majority of the catalytic domain encoded in
the ADAR2 gene between the two loxP sites. (B) An AR2 mouse at
12months of age (left panel) exhibits a low grip strength score with an
abnormal hind limb and tail posture compared to a control littermate (right
panel). (C) Locomotion and walking distances for an interval of 1min were
traced using a video capture system. An AR2 mouse at 12months of age
(red line) showed low locomotion levels compared to a control littermate
(blue line).
denervated NMJs was higher in AR2 mice at 4months of age
than at 12months, whereas the proportion of reinnervated NMJs
was higher in AR2 mice at 12months of age than at 4months
of age (Figure 5D). These results indicate that degeneration of
ADAR2-lacking AHCs led to the degeneration of their axons with
a resultant denervation of NMJs, which were reinnervated by col-
laterally sprouted axons of the ADAR2-expressing normal AHCs.
With the degeneration of AHCs, a marked proliferation of glial
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FIGURE 4 |The phenotype of conditional ADAR2 knockout mice (AR2)
and slow mice.We generated two lines of conditional ADAR2 knockout
mice with different Cre expression patterns: AR2
(ADAR2ﬂox/ﬂox/VAChT-Cre.Fast) mice express Cre in progressively larger
proportions of motor neurons, reaching ∼50% of the maximum by
postnatal week 5. Slow (ADAR2ﬂox/ﬂox/VAChT-Cre.Slow) mice express Cre
more slowly, reaching ∼50% of motor neurons by 8months of age. (A)
Rotarod performance of AR2 mice (ﬁlled circle; n=28) and Slow mice
(open circle; n=33). Using a mouse-speciﬁc rotarod (SN-445,
Neuroscience Corp., Tokyo Japan), the maximal time before falling at 10 rpm
during a 180-s period among three trials was used for the analysis. The
scores are indicated as a percentage of the performance by control mice
(n=15), which exhibited full performance until approximately 12months of
age, followed by a slightly lower performance (greater than 164.5±6.4 s)
until 24months. (B) Grip power measured with a dynamometer
(NS-TRM-M, Neuroscience, Japan). The score is indicated as a percentage
of the performance by control mice. (C) AR2 mice had long life spans, but
the rate of death increased after month 18 compared to control mice.
ﬁbrillary acidic protein (GFAP)-positive astrocytes and MAC2-
positive microglial cells was detected in the anterior horns of AR2
mice (Figures 6A,B).
FIGURE 5 | Loss of ADAR2-deficient motor neurons. (A) Degenerating
large motor neurons in the anterior horn (AHC) of AR2 mice at 2months of
age (Nissl staining). Scale bar, 50μm. (B)The numbers (mean±SEM) of
total AHCs (green columns), ADAR2-positive AHCs (blue columns), and
ADAR2-negative AHCs (red columns) in AR2 mice at different ages (2, 6, 9,
12months). The number of AHCs signiﬁcantly decreased in AR2 mice after
2months of age due to the reduction of ADAR2-lacking AHCs (*p<0.01,
repeated ANOVA). (C)The ventral root (L5) of AR2 mice at 4months of age
showing degenerating dark axons. Scale bar, 20μm. (D) Neuromuscular
junctions (NMJs) and distal motor nerve axons. The quadriceps muscles
from an AR2 mouse (Reinnervated, Denervated) at 12months of age and
an age-matched, wild-type mouse (Ctl; normal) are stained with
tetramethylrhodamine-bungarotoxin (BTX; red) and immunostained
concomitantly with anti-synaptophysin and neuroﬁlament antibodies
(SYN/NF; green). The endplates (red) were counted as “innervated” if they
were merged with axon terminals (yellow). A thick axon terminal in the Ctl
mouse innervates each endplate, whereas in AR2 mice, some NMJs are
innervated by axons that simultaneously innervate more than one NMJ
(reinnervated NMJ), and other NMJs are devoid of axon terminals
(denervated NMJs; white arrow).
Other than the motor neurons in the spinal cord, large neurons
in the facial (VII), and hypoglossal nerve nuclei (XII) in AR2 mice
at 12months of agewere signiﬁcantly decreased innumber. In con-
trast, the number of neurons in the nuclei of the extraocularmotor
nerves (III, IV, VI) was not decreased (Figure 6C). Conversely,
GluA2Q/R site editingwas signiﬁcantly decreased in the oculomo-
tor nerve nuclei (89.7% of control mice, p = 0.0048) and the facial
nerve nuclei (83.3% of control mice, p = 0.0017) of AR2 mice at
12months of age (Figure 6C). These results indicate that subsets of
motor neurons, including those in the oculomotor nerve nucleus,
are relatively resistant to cell death mediated by deﬁcient ADAR2.
Notably, the selective sparing of motor neurons that innervate
the extraocular muscles as compared to those that innervate the
bulbar and limb muscles is characteristically seen in ALS patients.
Motor neurons in the nuclei of the oculomotor nerves are much
less vulnerable in ALS patients. Notably, the expression of Ca2+-
binding proteins, particularly parvalbumin, is high in oculomotor
neurons and low in the facial and spinal motor neurons (Ince et al.,
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FIGURE 6 | Reactive glial cells in the spinal anterior horns and cranial
motor nerve nuclei of AR2 mice (A,B). Immunohistochemistry in the
anterior horn (C5) and motor trigeminal nuclei (Vm). There was an increase
in GFAP- and MAC2-immunoreactivity in the spinal anterior horn of the AR2
mice, indicating the proliferation of activated astrocytes and microglia in
association with motor neuron degeneration. m: months of age, inset;
activated astroglia. Scale bars, 100μm (GFAP) and 50μm (insets and
Mac2). (C) In AR2 mice at 12months of age, the number of large neurons
in the cranial nuclei of Vm, VII, and XII were lower than those in
age-matched control mice, whereas those in the cranial nuclei III, IV, and VI
were not. The GluA2 Q/R site editing efﬁciency was decreased in III, VII,
and AH, indicating that the cranial motor neurons that innervate extraocular
muscles are exceptionally resistant to deﬁcient-ADAR2-mediated neuronal
death.
1993). It has been shown that over-expression of parvalbumin
attenuated kainate-induced Ca2+ transients and protected spinal
motor neurons from the resultant neurotoxicity in parvalbumin
transgenic mice (Van Den Bosch et al., 2002). In AR2 mice and in
patients with sporadic ALS, it is likely that neurons with abundant
parvalbumin, such as ocular motor neurons, are more resistant to
Ca2+ overload from Ca2+-permeable AMPA receptors than those
with low parvalbumin levels, such as spinal motor neurons.
THE CRUCIAL ROLE OF GluA2 RNA EDITING IN THE DEATH OF
ADAR2-LACKING MOTOR NEURONS IN AR2 MICE
ADAR2 predominantly catalyzes the RNA editing at theQ/R site of
GluA2 both in vivo and in vitro (Melcher et al., 1996;Higuchi et al.,
2000; Wang et al., 2000), but there are numerous A-to-I positions
in mammalian brains, some of which are speciﬁcally catalyzed
by ADAR2. Among the A-to-I positions speciﬁcally mediated by
ADAR2 (Nishimoto et al., 2008), we found a signiﬁcant reduction
in the editing efﬁciency at the GluK2 (GluR6) Q/R site (AR2 mice
vs. control mice, 15.3 vs. 31.8%, p = 0.04416) and at the K/E site
of cytoplasmic fragile X mental retardation interacting protein
2 (CYFIP2) mRNA (Figure 7). These results indicate that RNA
editing at the ADAR2-mediated A-to-I positions is universally
defective in AR2 motor neurons.
To examine the possible role of defective RNA editing at A-
to-I positions other than the GluA2 Q/R site in motor neuron
death, we investigated the effects of edited GluA2 expression in
ADAR2-lacking motor neurons (Figure 8). We exchanged the
endogenous GluA2 alleles that encoded Q at the Q/R site in AR2
mice with the GluR-BR alleles (Kask et al., 1998), which encode R
at the Q/R site of GluA2. This exchange circumvented the need for
ADAR2-mediated RNA editing in the expression of edited GluA2.
We intercrossed ADAR2ﬂox/+/VAChT-Cre.Fast/GluR-BR/+ mice to
generate AR2/GluR-BR/R mice. AR2/GluR-BR/R mice (AR2res)
were phenotypically normal and had full motor function until
FIGURE 7 |The failure of CYFIP2 K/E site editing and GluA2 Q/R site
editing in ADAR2-lacking motor neurons.When the extent of RNA
editing was measured in the pooled lysates of three motor neurons
obtained from AR2 mice, the proportions of CYFIP2 mRNA edited at the
lysine/glutamic acid (K/E) site and those of Q/R site-edited GluA2 mRNA
were lower in the lysates containing ADAR2-lacking motor neurons. This
ﬁnding indicates that ADAR2 speciﬁcally mediates A-to-I conversion at the
K/E site of CYFIP2 pre-mRNA. Ratios in abscissa indicate the number of
ADAR2-expressing motor neurons (ﬁlled circle) and ADAR2-lacking motor
neurons (open circle) in the three motor neuron lysates of AR2 mice. (see
Figure 10).
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FIGURE 8 | Do other ADAR2 substrates play a role in the death of
ADAR2-lacking motor neurons?There is a possibility that the death of
motor neurons in AR2 mice is mediated by a failure of RNA editing at
ADAR2-mediated A-to-I positions other than the GluA2 Q/R site.
6months of age. The AHCs, including those lacking ADAR2 due
to Cre-mediated recombination, were viable in AR2res mice at
6months of age, and the total number of AHCs was the same as
in age-matched control mice (Figure 9A). Consistent with a lack
of AHC loss, there was no detectable increase in GFAP- or MAC2-
immunoreactivity in the anterior horns (Hideyama et al., 2010).
These results demonstrate that an ADAR2 deﬁciency induces the
slow death of motor neurons speciﬁcally via the GluA2 Q/R site
editing failure (Figure 9B).
DEATH OF MOTOR NEURONS IN HETEROZYGOUS AR2
(HETEROAR2) MICE
The results of our experiments with the AR2 mice indicate that
deﬁcient-ADAR2-mediated death of motor neurons in the spinal
cord and the cranial motor nerve nuclei is speciﬁcally mediated
by the failure to edit the GluA2 Q/R site. In the ALS spinal cord,
some motor neurons express unedited GluA2, but others express
only edited GluA2. The majority of motor neurons expressing
unedited GluA2 also express edited GluA2 (Kawahara et al., 2004).
Furthermore, a recent immunohistochemical study demonstrated
that both ADAR2-positive and ADAR2-negative motor neurons
coexist in patients with sporadic ALS, whereas all motor neurons
areADAR2-positive in control subjects (Aizawa et al., 2010). How-
ever,wedonot know the expression level of ADAR2 that is required
to edit all GluA2 mRNA or the proportion of unedited GluA2 that
is not harmful to motor neurons.
To answer these questions, we investigated the extent of GluA2
Q/R site editing in motor neurons lacking one ADAR2 allele
in the heterozygous ADAR2ﬂox/+/VAChT-Cre (HeteroAR2) mice.
Additionally, we investigated whether motor neurons lacking one
ADAR2 allele can survive in HeteroAR2 mice compared to AR2
and control mice. In HeteroAR2 mice, the proportion of motor
neurons that express Cre is the same as in AR2 mice; the Cre-
expressing motor neurons express only one ADAR2 allele. There-
fore, if the expression level of ADAR2 in normal motor neurons
FIGURE 9 |The crucial role of GluA2 Q/R site editing in the death of
ADAR2-deficient motor neurons. (A) AR2/GluR-BR/R mice (AR2res) are
phenotypically normal with a preservation of ADAR2-lacking AHCs that
account for 30% of the total AHCs at 6months of age. (B) A scheme
illustrating that the death of ADAR2-lacking motor neurons due to failure to
edit the GluA2 Q/R site in the AR2 mice is rescued in the AR2res mice. The
exonic Q codon (CAG) for the Q/R site of GluA2 is substituted by an R
codon (CGG) in the endogenous GluA2 alleles, and only edited GluA2 is
expressed in the absence of ADAR2 activity.
is sufﬁciently above the requirement to edit the Q/R site of all
GluA2 mRNAs expressed (i.e., threefold or more), all motor neu-
rons would express only edited GluA2. However, if normal motor
neurons express ADAR2 at a level that is only sufﬁcient to edit
GluA2 (i.e., less than twofold), motor neurons with one ADAR2
allele would express abundant unedited GluA2 and die. Further-
more, if motor neurons expressing one ADAR2 allele express both
edited and unedited GluA2 and undergo degeneration in Het-
eroAR2 mice, we would expect to ﬁnd the proportion of unedited
GluA2 that is toxic to motor neurons.
When the extent of GluA2 Q/R site editing was examined in
the lysates of three laser-captured motor neurons of 2-month-
old HeteroAR2 mice, GluA2 Q/R site editing was incomplete in
approximately 20% of the lysates (Figure 10). The proportion of
edited GluA2 was above 70% in all the lysates; however, in the
AR2 mice of the same age, unedited GluA2 was detected in more
than 60% of the lysates of three motor neurons, and the editing
efﬁciency was 0 in 7% of the lysates examined (Hideyama et al.,
2010). Therefore, it is likely that motor neurons exhibit consider-
able editing activity in the expression of only one ADAR2 allele;
however, this is not sufﬁcient to edit the Q/R site of all GluA2
mRNA in HeteroAR2 mice.
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FIGURE 10 | Some of the motor neurons from HeteroAR2 mice express
Q/R site-unedited GluA2 mRNA. A frequency histogram of editing
efﬁciency at the GluA2 Q/R site in the lysates of three motor neurons
obtained from heterozygous ADAR2ﬂox/+/VAChT-Cre.Fast (HeteroAR2) mice
and control mice (Ctl). Motor neurons (252 neurons) were dissected from
14-μm-thick frozen sections of spinal cord obtained with a laser
microdissector from HeteroAR2 mice at 2months of age (n=4). The
lysates containing three motor neurons (84 specimens) were subjected to a
measurement of the editing efﬁciency of GluA2 mRNA at the Q/R site. This
histogram shows that approximately a quarter of the lysates, or 15–20% of
AHCs, express unedited GluA2. Notably, the extent of GluA2 editing is
above 70%, which is in contrast with the AR2 mice, in which approximately
8% of the lysates expressed only unedited GluA2. All 96 motor neurons
dissected from control mice (Ctl; ADAR2ﬂox/ﬂox and VAChT-Cre mice)
expressed only Q/R site-edited GluA2 mRNA.
We also examined whether there was a loss of AHCs in Het-
eroAR2 mice. The extent of AHC loss in HeteroAR2 mice was
approximately half (26%) of that observed in AR2 mice (46%)
at 12months of age (Figure 11A). A moderate increase in GFAP-
and MAC2-immunoreactivity was detected in the anterior horns
of HeteroAR2 mice at 12months of age (Figure 11B). Het-
eroAR2 mice did not exhibit signiﬁcant behavioral changes until
12months of age, indicating that mild loss of motor neurons
would not affect motor function at least until 1 year of age.
These results show that one ADAR2 gene allele is sufﬁcient to
edit all GluA2 mRNA in half of the motor neurons but is insuf-
ﬁcient in the other half of motor neurons. Because the editing
efﬁciency was above 70% in the motor neuron lysates of Het-
eroAR2 mice, it is likely that the minimal expression level of
ADAR2 required for complete GluA2 editing is slightly higher
than half of the normal level in mouse motor neurons.
More than a quarter of the motor neurons in HeteroAR2 mice
underwent degeneration by the age of 1 year. Furthermore, from
the results of our experiments with AR2 and AR2res (Hideyama
et al., 2010), it is likely that only the motor neurons expressing
unedited GluA2 have undergone degeneration. The proportions
of unedited GluA2 are 30% at the maximum and less than 10%
in the majority of motor neurons in HeteroAR2 mice, indicating
that expression of unedited GluA2, even in a small proportion, is
not favorable for the survival of motor neurons in mice.
THE ADAR2 HYPOTHESIS FOR SPORADIC ALS
Progression of ALS is rather slow, taking several years to progress
from the onset of the initial symptoms to death, which results
from failure of the respiratory muscles. From our ﬁndings in
FIGURE 11 | HeteroAR2 mice display a loss of AHCs. (A)The numbers
(mean±SEM) of ADAR2-positive AHCs (black columns) and those of
ADAR2-lacking AHCs (gray columns) in HeteroAR2 mice at 12months of
age compared to age-matched AR2 and control mice. There was a loss of
AHCs in the HeteroAR2 mice (Hetero; *p<0.01) but to a lesser extent than
in the AR2 mice (#p<0.01). (B) Immunohistochemistry in the anterior horn
of the spinal cord (C5). There was an increase in GFAP-immunoreactivity but
to a lesser extent than in the AR2 mice (upper panel) and a slight increase
of MAC2-immunoreactivity (lower panel) in the HeteroAR2 mice. Scale
bars: 100μm (upper panel) and 50μm (insets and lower panel).
the AR2 mice, we learned that some ADAR2-lacking motor neu-
rons died within 1month of ADAR2 knockout, whereas others
could survive more than 1 year even with only unedited GluA2
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FIGURE 12 |The ADAR2-GluA2 hypothesis for ALS pathogenesis. ADAR2
activity is preserved well above the level that enables motor neurons to edit
the Q/R site of all GluA2 mRNA expressed in healthy individuals (normal;
neurons in blue). In the motor neurons of sporadic ALS patients, ADAR2
activity progressively decreases, and the ADAR2 activity in all motor neurons
is initially low but is within a level that is sufﬁcient to edit the Q/R site of all
GluA2 mRNA; thus, motor neurons function normally (pre-clinical ALS).With a
decline of ADAR2 activity, some motor neurons express ADAR2 below a
threshold level for GluA2 RNA editing (dotted line) and express unedited
GluA2 (neurons in black). These motor neurons can survive for some period of
time, but they do not function normally and ultimately enter into the death
cascade in a stochastic manner.With the progressive decline of ADAR2
activity, the number of motor neurons expressing unedited GluA2, and
therefore those destined to die, increases. Patients and neurologists
recognize ALS only after a considerable proportion of motor neurons has
already malfunctioned (neurons in black) or been lost (neurons in gray).
expression (Hideyama et al., 2010). Therefore, it is likely that the
timing of motor neuron death may be a stochastic phenomenon
that depends on environmental factors and the level of the com-
pensatory activity in the individual neurons, including the ﬁring
frequency of the motor neurons, the strength of the Ca2+ buffer-
ing system, and the density of functional Ca2+-permeable AMPA
receptors. Furthermore, the results from theHeteroAR2mice indi-
cate that motor neurons expressing unedited GluA2, regardless of
the proportion, are destined to die in sporadic ALS patients.
The progressive downregulation of ADAR2 activity increases
the number of motor neurons expressing unedited GluA2 in
sporadicALS.Themechanismunderlying the reductionofADAR2
activity in ALS motor neurons is not clear; however, considering
that inefﬁcient GluA2 RNA editing was found only in sporadic
cases (Kawahara et al., 2006), undeﬁned postnatal factors regulat-
ing the ADAR2 activity should not be neglected. Because ADAR2
SNPs are associated with longevity syndrome (Sebastiani et al.,
2009) and the age-dependent downregulation of ADAR2 activ-
ity has been shown in human brains (Nicholas et al., 2011), the
acceleration of age-related neuronal dysfunction may have a role
in the progressive reduction of ADAR2 activity in ALS motor
neurons.
We recently reported that TDP-43 pathology, which is a hall-
mark of ALS, appeared only in the motor neurons lacking ADAR2
immunoreactivity in patients with sporadic ALS (Aizawa et al.,
2010). It is likely thatmotor neurons lackingADAR2 immunoreac-
tivity represent those expressing unedited GluA2, and motor neu-
rons expressing ADAR2 immunoreactivity with normal TDP-43
immunoreactivity represent those expressing only edited GluA2.
Because a reduction of ADAR2 likely begins before motor neu-
rons express unedited GluA2 in ALS motor neurons, TDP-43
pathology may be induced by the expression of unedited GluA2
rather than TDP-43 pathology causes reduced ADAR2 activity.
We do not know whether the reduction of ADAR2 immunore-
activity in the ALS motor neurons results from a reduced gene
expression or acceleratedADAR2protein degradation catalyzed by
Ca2+-activated proteinase as demonstrated in ischemic rat brains
(Mahajan et al., 2011).
Based on this evidence, we propose a hypothesis for the patho-
genesis of sporadic ALS. ALS motor neurons express progressively
lower ADAR2 activity before manifesting an ALS phenotype, and
the pathological process commences when motor neurons begin
to express unedited GluA2. Motor neurons expressing unedited
GluA2 do not function normally but do not immediately die.
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The timing of the entry of these motor neurons into the death
cascade may be regulated in a stochastic manner. With a sequen-
tial progression of these events, the pool of normally functioning
motor neurons expressing only editedGluA2decreases,whichulti-
mately induces theALSphenotype in patients (Figure 12). Because
mutations in the coding molecules of the genes involved in RNA
regulation, including TDP-43 and FUS/TLS, were recently found
in patients with familial ALS (Arai et al., 2006; Neumann et al.,
2006; Kwiatkowski et al., 2009; Vance et al., 2009), dysregulation
of RNA metabolism in ALS pathogenesis is now attracting the
interest of researchers (Lemmens et al., 2010). Because ADAR2 is
an RNA regulatory molecule, future studies are needed to eluci-
date the molecular link between abnormalities of theseALS-linked
RNA regulatory molecules with the ADAR2 downregulation in
ALS motor neurons. Forcing motor neurons to express only edited
GluA2 may be a future therapy for sporadic ALS.
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